Broncho-munal hard capsules 7 mg blister 10 pcs.

$31.48

Broncho-munal contains a lyophilized lysate of bacteria that most often cause respiratory tract infections, including Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Streptococcus viridans, Streptococcus pyogenes, Moraxella catarrhalis.

Broncho-munal contains a lyophilized lysate of bacteria that most often cause respiratory tract infections, including Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Streptococcus viridans, Streptococcus pyogenes, Moraxella catarrhalis.

The drug stimulates the body’s natural defenses against respiratory tract infections, reducing the frequency, duration, and severity of respiratory tract infections, and also reduces the need for antibiotics.

The drug activates the cellular and humoral immune response of the respiratory tract mucosa and other immunocompetent structures of the body. It also stimulates the nonspecific immune response of the body. In preclinical and clinical studies, the following effects of the drug on the body’s defense mechanisms have been demonstrated:

  • stimulates alveolar macrophages, which secrete cytokines that protect the body from infections;
  • increases the number of CD4 T-lymphocyte populations;
  • activates peripheral mononuclear cells that perform a protective function;
  • increases the concentration of secretory IgA on the mucous membranes of the respiratory tract and digestive tract;
  • stimulates the formation of protective adhesive molecules;
  • reduces the content of IgE in blood plasma, which can inhibit the development of hypersensitivity reactions.

Indication

Use for the prevention of recurrent respiratory tract infections.

Contraindication

Hypersensitivity to the active substance or any excipient included in the medicinal product.

Composition

Active ingredients: 1 capsule contains 7 mg of lyophilized lysate of bacteria Haemophilus influenzae, Streptococcus (Diplococcus) pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Moraxella (Branhamella/Neisseria) catarrhalis;

Excipients: propyl gallate, sodium glutamate, mannitol (E 421), magnesium stearate, pregelatinized starch;

Shell: indigotine (E 132), titanium dioxide (E 171), gelatin.

Method of administration and doses

Adults and adolescents aged 12 years and over

Cycle of preventive treatment of recurrent respiratory tract infections: 1 capsule per day on an empty stomach for 10 consecutive days per month, for 3 consecutive months.

Treatment can be initiated during the acute phase of respiratory tract infections in combination with other treatments.

The drug should be taken in the morning on an empty stomach.

If the patient forgets to take the drug, it should be taken the next morning.

Overdose

No clear clinical symptoms of drug overdose have been observed. No cases of overdose have been reported. In case of overdose, consult a doctor.

Adverse reactions

The reported adverse reactions are classified below according to MedDRA system organ class and frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), including isolated reports, frequency unknown (cannot be estimated from the available data).

Immune system disorders: uncommon – hypersensitivity reactions (erythematous rash, generalized skin rash, erythema, edema, eyelid edema, facial edema, peripheral edema, swelling, facial swelling, pruritus, generalized pruritus, dyspnea).

From the nervous system: frequent – headache.

Respiratory, thoracic and mediastinal disorders: frequent – cough.

Gastrointestinal: frequent – diarrhea, abdominal pain; infrequent – nausea, vomiting.

Skin and subcutaneous tissue disorders: common – rash; uncommon – urticaria; frequency unknown – angioedema.

General disorders: infrequent – increased fatigue; rare – fever.

In case of persistent gastrointestinal or respiratory disorders, treatment should be discontinued. In case of skin reactions, treatment should also be interrupted, as these manifestations may be allergic in nature.

Application features

Use during pregnancy or breastfeeding

The medicine is not used during the first three months of pregnancy.

Patients who intend to become pregnant or who have become pregnant should inform their doctor.

Safety during pregnancy has not been established, therefore it is advisable to avoid the use of this medicine during pregnancy.

No studies have been conducted in breastfeeding women. Therefore, caution should be exercised during breastfeeding.

Children

This dosage can be used in children over 12 years of age.

Ability to influence reaction speed when driving vehicles or other mechanisms

Does not affect the ability to drive a car or use mechanisms.

Interaction with other medicinal products and other types of interactions

The interaction of the drug with other medications is currently unknown.

Storage conditions

Store at a temperature not exceeding 25 °C in the original packaging in order to protect from moisture.

Keep out of reach of children.

Shelf life – 5 years.

Reviews

There are no reviews yet.

Be the first to review “Broncho-munal hard capsules 7 mg blister 10 pcs.”

Your email address will not be published. Required fields are marked *